Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell TransplantationReportar como inadecuado




Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BioMed Research International - Volume 2014 2014, Article ID 982504, 8 pages -

Research Article

Hematology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, #222 Banpo-daero, Seocho-Gu, Seoul 137-701, Republic of Korea

Department of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea

Received 20 February 2014; Accepted 18 April 2014; Published 6 May 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 Sung-Eun Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The current definition of complete response CR in multiple myeloma MM includes negative serum and urine immunofixation IFE tests and <5% bone marrow plasma cells BMPCs. However, many studies of the prognostic impact of pretransplant response have not included BMPCs. We evaluated the prognostic impact of BMPC assessment before peripheral blood stem cell PBSC mobilization on subsequent transplant outcomes. BMPCs were assessed by CD138, kappa, and lambda immunostaining in 106 patients. After a median followup of 24.5 months, patients with <5% BMPCs had a significantly better progression-free survival PFS compared to those with ≥5% BMPCs . Patients with <5% BMPCs + serologic CR showed superior PFS compared to those with <5% BMPCs + serologic non-CR or ≥5% BMPCs + serologic non-CR . Interestingly, the prognostic impact of BMPCs was more apparent for patients who did not achieve a serologic CR compared to those with a serologic CR . We concluded that IFE negativity and <5% BMPCs before PBSC mobilization were important factors to predict PFS in patients with MM undergoing ASCT. Particularly, a significant impact of <5% BMPCs was observed in patients who did not achieve IFE negativity.





Autor:

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados